Visionary Wealth Advisors bought a new stake in shares of Ultralife Corporation (NASDAQ:ULBI - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,109,170 shares of the technology company's stock, valued at approximately $7,010,000. Visionary Wealth Advisors owned 6.66% of Ultralife at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. XTX Topco Ltd boosted its stake in shares of Ultralife by 19.9% during the 4th quarter. XTX Topco Ltd now owns 15,456 shares of the technology company's stock worth $88,000 after acquiring an additional 2,569 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Ultralife by 30.7% in the 4th quarter. Bank of America Corp DE now owns 12,067 shares of the technology company's stock worth $90,000 after purchasing an additional 2,836 shares in the last quarter. Lazard Asset Management LLC raised its holdings in Ultralife by 1,650.0% in the 2nd quarter. Lazard Asset Management LLC now owns 5,565 shares of the technology company's stock worth $49,000 after purchasing an additional 5,247 shares during the period. Empowered Funds LLC bought a new position in Ultralife in the 4th quarter worth $44,000. Finally, Janney Montgomery Scott LLC raised its holdings in Ultralife by 2.0% in the 1st quarter. Janney Montgomery Scott LLC now owns 518,000 shares of the technology company's stock worth $3,377,000 after purchasing an additional 10,200 shares during the period. 30.68% of the stock is owned by hedge funds and other institutional investors.
Ultralife Stock Performance
ULBI opened at $6.77 on Tuesday. The company has a 50 day simple moving average of $6.09 and a two-hundred day simple moving average of $6.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.87 and a quick ratio of 1.30. The firm has a market cap of $112.81 million, a P/E ratio of -16.92 and a beta of 0.80. Ultralife Corporation has a 1-year low of $4.90 and a 1-year high of $8.25.
Ultralife (NASDAQ:ULBI - Get Free Report) last released its earnings results on Friday, August 7th. The technology company reported $0.19 earnings per share for the quarter, meeting analysts' consensus estimates of $0.19. Ultralife had a negative net margin of 3.50% and a positive return on equity of 2.75%. The company had revenue of $47.94 million for the quarter, compared to analysts' expectations of $55.00 million.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings lowered Ultralife from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, June 12th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Ultralife currently has an average rating of "Sell".
Check Out Our Latest Stock Analysis on ULBI
Ultralife Company Profile
(
Free Report)
Ultralife Corporation NASDAQ: ULBI develops, manufactures and sells a broad range of energy and communications products for defense, medical, automotive and consumer electronics markets. The company operates through two primary segments: Power Systems and Communications Systems. In its Power Systems segment, Ultralife produces lithium-ion rechargeable cells and battery packs, primary lithium batteries, alkaline and rechargeable battery packs, chargers and battery accessories designed to meet demanding performance and safety requirements.
Further Reading
Want to see what other hedge funds are holding ULBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultralife Corporation (NASDAQ:ULBI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Ultralife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultralife wasn't on the list.
While Ultralife currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.